Zinc Supplementation and Infections in Older Medical Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorHerlev Hospital
About this trial
The goal of this clinical trial is to learn about the effect of zinc supplementation once daily for 12 months in older acute medical patients. The main question it aims to answer is:
• Can daily zinc supplementation for 12 months increase Days Alive and Out of Hospital (DAOH)? Researchers will compare zinc supplementation to a control group, a group who do not receive zinc supplementation, to see if zinc supplementation can increase Days Alive and Out of Hospital, reduce antibiotic use, readmissions and mortality.
Participants will take 22 mg zinc supplementation once daily for 12 months or not.
The researchers will draw data on readmissions, antibiotic use and mortality during the 12 months follow-up period.
Eligibility criteria
Qualifiers
All medical patients aged ≥ 65 years assessed at the Medical Emergency Department, Herlev Hospital
Disqualifiers
Self-supplementing with zinc at time of assessment (> 10 mg zinc/day)
Terminal illness (life expectancy < 6 months, estimated by Clinical Frailty Scale ≥8)
Patients receiving parenteral nutrition (partial or complete)
Patients treated with hemodialysis or peritoneal dialysis
Trial design
Treatments tested in this trial
- Zinc (zinc sulphate)
Treatment groups
8,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Herlev Hospital
Lead sponsor
Independent Research Fund Denmark
Collaborator
The Novo Nordic Foundation
Collaborator
Source ClinicalTrials.gov